Association of Combined Anti-Ro52/TRIM21 and Anti-Ro60/SSA Antibodies With Increased Sjögren Disease Severity Through Interferon Pathway Activation
© 2023 The Authors. Arthritis & Rheumatology published by Wiley Periodicals LLC on behalf of American College of Rheumatology..
OBJECTIVE: The biologic diagnosis of primary Sjögren disease (SjD) mainly relies on anti-Ro60/SSA antibodies, whereas the significance of anti-Ro52/TRIM21 antibodies currently remains unclear. The aim of this study was to characterize the clinical, serological, biologic, transcriptomic, and interferon profiles of patients with SjD according to their anti-Ro52/TRIM21 antibody status.
METHODS: Patients with SjD from the European PRECISESADS (n = 376) and the Brittany Diagnostic Suspicion of primitive Sjögren's Syndrome (DIApSS); (n = 146) cohorts were divided into four groups: double negative (Ro52-/Ro60-), isolated anti-Ro52/TRIM21 positive (Ro52+), isolated anti-Ro60/SSA positive (Ro60+), and double-positive (Ro52+/Ro60+) patients. Clinical information; EULAR Sjögren Syndrome Disease Activity Index, a score representing systemic activity; and biologic markers associated with disease severity were evaluated. Transcriptome data obtained from whole blood by RNA sequencing and type I and II interferon signatures were analyzed for PRECISESADS patients.
RESULTS: In the DIApSS cohort, Ro52+/Ro60+ patients showed significantly more parotidomegaly (33.3% vs 0%-11%) along with higher β2-microglobulin (P = 0.0002), total immunoglobulin (P < 0.0001), and erythrocyte sedimentation rate levels (P = 0.002) as well as rheumatoid factor (RF) positivity (66.2% vs 20.8%-25%) compared to other groups. The PRECISESADS cohort corroborated these observations, with increased arthritis (P = 0.046), inflammation (P = 0.005), hypergammaglobulinemia (P < 0.0001), positive RF (P < 0.0001), leukopenia (P = 0.004), and lymphopenia (P = 0.009) in Ro52+/Ro60+ patients. Cumulative EULAR Sjögren Syndrome Disease Activity Index results further confirmed these disparities (P = 0.002). Transcriptome analysis linked anti-Ro52/TRIM21 antibody positivity to interferon pathway activation as an underlying cause for these clinical correlations.
CONCLUSION: These results suggest that the combination of anti-Ro52/TRIM21 and anti-Ro60/SSA antibodies is associated with a clinical, biologic, and transcriptional profile linked to greater disease severity in SjD through the potentiation of the interferon pathway activation by anti-Ro52/TRIM21 antibodies.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:76 |
|---|---|
| Enthalten in: |
Arthritis & rheumatology (Hoboken, N.J.) - 76(2024), 5 vom: 01. Apr., Seite 751-762 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Bettacchioli, Eléonore [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 25.04.2024 Date Revised 25.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/art.42789 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36620677X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36620677X | ||
| 003 | DE-627 | ||
| 005 | 20240426233459.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231227s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/art.42789 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1388.xml |
| 035 | |a (DE-627)NLM36620677X | ||
| 035 | |a (NLM)38130019 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Bettacchioli, Eléonore |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Association of Combined Anti-Ro52/TRIM21 and Anti-Ro60/SSA Antibodies With Increased Sjögren Disease Severity Through Interferon Pathway Activation |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.04.2024 | ||
| 500 | |a Date Revised 25.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 The Authors. Arthritis & Rheumatology published by Wiley Periodicals LLC on behalf of American College of Rheumatology. | ||
| 520 | |a OBJECTIVE: The biologic diagnosis of primary Sjögren disease (SjD) mainly relies on anti-Ro60/SSA antibodies, whereas the significance of anti-Ro52/TRIM21 antibodies currently remains unclear. The aim of this study was to characterize the clinical, serological, biologic, transcriptomic, and interferon profiles of patients with SjD according to their anti-Ro52/TRIM21 antibody status | ||
| 520 | |a METHODS: Patients with SjD from the European PRECISESADS (n = 376) and the Brittany Diagnostic Suspicion of primitive Sjögren's Syndrome (DIApSS); (n = 146) cohorts were divided into four groups: double negative (Ro52-/Ro60-), isolated anti-Ro52/TRIM21 positive (Ro52+), isolated anti-Ro60/SSA positive (Ro60+), and double-positive (Ro52+/Ro60+) patients. Clinical information; EULAR Sjögren Syndrome Disease Activity Index, a score representing systemic activity; and biologic markers associated with disease severity were evaluated. Transcriptome data obtained from whole blood by RNA sequencing and type I and II interferon signatures were analyzed for PRECISESADS patients | ||
| 520 | |a RESULTS: In the DIApSS cohort, Ro52+/Ro60+ patients showed significantly more parotidomegaly (33.3% vs 0%-11%) along with higher β2-microglobulin (P = 0.0002), total immunoglobulin (P < 0.0001), and erythrocyte sedimentation rate levels (P = 0.002) as well as rheumatoid factor (RF) positivity (66.2% vs 20.8%-25%) compared to other groups. The PRECISESADS cohort corroborated these observations, with increased arthritis (P = 0.046), inflammation (P = 0.005), hypergammaglobulinemia (P < 0.0001), positive RF (P < 0.0001), leukopenia (P = 0.004), and lymphopenia (P = 0.009) in Ro52+/Ro60+ patients. Cumulative EULAR Sjögren Syndrome Disease Activity Index results further confirmed these disparities (P = 0.002). Transcriptome analysis linked anti-Ro52/TRIM21 antibody positivity to interferon pathway activation as an underlying cause for these clinical correlations | ||
| 520 | |a CONCLUSION: These results suggest that the combination of anti-Ro52/TRIM21 and anti-Ro60/SSA antibodies is associated with a clinical, biologic, and transcriptional profile linked to greater disease severity in SjD through the potentiation of the interferon pathway activation by anti-Ro52/TRIM21 antibodies | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a SS-A antigen |2 NLM | |
| 650 | 7 | |a Ribonucleoproteins |2 NLM | |
| 650 | 7 | |a RO60 protein, human |2 NLM | |
| 650 | 7 | |a SS-A antibodies |2 NLM | |
| 650 | 7 | |a Interferons |2 NLM | |
| 650 | 7 | |a 9008-11-1 |2 NLM | |
| 650 | 7 | |a Autoantibodies |2 NLM | |
| 650 | 7 | |a Antibodies, Antinuclear |2 NLM | |
| 650 | 7 | |a Autoantigens |2 NLM | |
| 650 | 7 | |a RNA, Small Cytoplasmic |2 NLM | |
| 700 | 1 | |a Saraux, Alain |e verfasserin |4 aut | |
| 700 | 1 | |a Tison, Alice |e verfasserin |4 aut | |
| 700 | 1 | |a Cornec, Divi |e verfasserin |4 aut | |
| 700 | 1 | |a Dueymes, Maryvonne |e verfasserin |4 aut | |
| 700 | 1 | |a Foulquier, Nathan |e verfasserin |4 aut | |
| 700 | 1 | |a Hillion, Sophie |e verfasserin |4 aut | |
| 700 | 1 | |a Roguedas-Contios, Anne-Marie |e verfasserin |4 aut | |
| 700 | 1 | |a Benyoussef, Anas-Alexis |e verfasserin |4 aut | |
| 700 | 1 | |a Alarcon-Riquelme, Marta E |e verfasserin |4 aut | |
| 700 | 1 | |a Pers, Jacques-Olivier |e verfasserin |4 aut | |
| 700 | 1 | |a Devauchelle-Pensec, Valérie |e verfasserin |4 aut | |
| 700 | 0 | |a PRECISESADS Clinical Consortium, and PRECISESADS Sjögren Consortium |e verfasserin |4 aut | |
| 700 | 1 | |a Beretta, Lorenzo |e investigator |4 oth | |
| 700 | 1 | |a Vigone, Barbara |e investigator |4 oth | |
| 700 | 1 | |a Pers, Jacques-Olivier |e investigator |4 oth | |
| 700 | 1 | |a Saraux, Alain |e investigator |4 oth | |
| 700 | 1 | |a Devauchelle-Pensec, Valérie |e investigator |4 oth | |
| 700 | 1 | |a Cornec, Divi |e investigator |4 oth | |
| 700 | 1 | |a Jousse-Joulin, Sandrine |e investigator |4 oth | |
| 700 | 1 | |a Lauwerys, Bernard |e investigator |4 oth | |
| 700 | 1 | |a Ducreux, Julie |e investigator |4 oth | |
| 700 | 1 | |a Maudoux, Anne-Lise |e investigator |4 oth | |
| 700 | 1 | |a Vasconcelos, Carlos |e investigator |4 oth | |
| 700 | 1 | |a Tavares, Ana |e investigator |4 oth | |
| 700 | 1 | |a Neves, Esmeralda |e investigator |4 oth | |
| 700 | 1 | |a Faria, Raquel |e investigator |4 oth | |
| 700 | 1 | |a Brandão, Mariana |e investigator |4 oth | |
| 700 | 1 | |a Campar, Ana |e investigator |4 oth | |
| 700 | 1 | |a Marinho, António |e investigator |4 oth | |
| 700 | 1 | |a Farinha, Fátima |e investigator |4 oth | |
| 700 | 1 | |a Almeida, Isabel |e investigator |4 oth | |
| 700 | 1 | |a González-Gay, Miguel Ángel |e investigator |4 oth | |
| 700 | 1 | |a Blanco Alonso, Ricardo |e investigator |4 oth | |
| 700 | 1 | |a Corrales Martínez, Alfonso |e investigator |4 oth | |
| 700 | 1 | |a Cervera, Ricard |e investigator |4 oth | |
| 700 | 1 | |a Rodríguez-Pintó, Ignasi |e investigator |4 oth | |
| 700 | 1 | |a Espinosa, Gerard |e investigator |4 oth | |
| 700 | 1 | |a Lories, Rik |e investigator |4 oth | |
| 700 | 1 | |a De Langhe, Ellen |e investigator |4 oth | |
| 700 | 1 | |a Hunzelmann, Nicolas |e investigator |4 oth | |
| 700 | 1 | |a Belz, Doreen |e investigator |4 oth | |
| 700 | 1 | |a Witte, Torsten |e investigator |4 oth | |
| 700 | 1 | |a Baerlecken, Niklas |e investigator |4 oth | |
| 700 | 1 | |a Stummvoll, Georg |e investigator |4 oth | |
| 700 | 1 | |a Zauner, Michael |e investigator |4 oth | |
| 700 | 1 | |a Lehner, Michaela |e investigator |4 oth | |
| 700 | 1 | |a Collantes, Eduardo |e investigator |4 oth | |
| 700 | 1 | |a Ortega-Castro, Rafaela |e investigator |4 oth | |
| 700 | 1 | |a Aguirre-Zamorano, Angeles |e investigator |4 oth | |
| 700 | 1 | |a Escudero-Contreras, Alejandro |e investigator |4 oth | |
| 700 | 1 | |a Castro-Villegas, Carmen |e investigator |4 oth | |
| 700 | 1 | |a Jiménez Gómez, Yolanda |e investigator |4 oth | |
| 700 | 1 | |a Ortego, Norberto |e investigator |4 oth | |
| 700 | 1 | |a Concepción Fernández Roldán, María |e investigator |4 oth | |
| 700 | 1 | |a Raya, Enrique |e investigator |4 oth | |
| 700 | 1 | |a Jiménez Moleón, Inmaculada |e investigator |4 oth | |
| 700 | 1 | |a de Ramon, Enrique |e investigator |4 oth | |
| 700 | 1 | |a Quintero, Isabel Díaz |e investigator |4 oth | |
| 700 | 1 | |a Meroni, Pier Luigi |e investigator |4 oth | |
| 700 | 1 | |a Gerosa, Maria |e investigator |4 oth | |
| 700 | 1 | |a Schioppo, Tommaso |e investigator |4 oth | |
| 700 | 1 | |a Artusi, Carolina |e investigator |4 oth | |
| 700 | 1 | |a Chizzolini, Carlo |e investigator |4 oth | |
| 700 | 1 | |a Dufour, Aleksandra |e investigator |4 oth | |
| 700 | 1 | |a Wynar, Donatienne |e investigator |4 oth | |
| 700 | 1 | |a Kovács, Laszló |e investigator |4 oth | |
| 700 | 1 | |a Balog, Attila |e investigator |4 oth | |
| 700 | 1 | |a Deák, Magdolna |e investigator |4 oth | |
| 700 | 1 | |a Dulic, Sonja |e investigator |4 oth | |
| 700 | 1 | |a Kádár, Gabriella |e investigator |4 oth | |
| 700 | 1 | |a Hiepe, Falk |e investigator |4 oth | |
| 700 | 1 | |a Gerl, Velia |e investigator |4 oth | |
| 700 | 1 | |a Thiel, Silvia |e investigator |4 oth | |
| 700 | 1 | |a Rodriguez Maresca, Manuel |e investigator |4 oth | |
| 700 | 1 | |a López-Berrio, Antonio |e investigator |4 oth | |
| 700 | 1 | |a Aguilar-Quesada, Rocío |e investigator |4 oth | |
| 700 | 1 | |a Navarro-Linares, Héctor |e investigator |4 oth | |
| 700 | 1 | |a Ioannou, Yiannis |e investigator |4 oth | |
| 700 | 1 | |a Chamberlain, Chris |e investigator |4 oth | |
| 700 | 1 | |a Marovac, Jacqueline |e investigator |4 oth | |
| 700 | 1 | |a Alarcón Riquelme, Marta |e investigator |4 oth | |
| 700 | 1 | |a Gomes Anjos, Tania |e investigator |4 oth | |
| 700 | 1 | |a Beretta, Lorenzo |e investigator |4 oth | |
| 700 | 1 | |a Pers, Jacques-Olivier |e investigator |4 oth | |
| 700 | 1 | |a Saraux, Alain |e investigator |4 oth | |
| 700 | 1 | |a Vasconcelos, Carlos |e investigator |4 oth | |
| 700 | 1 | |a Cervera, Ricard |e investigator |4 oth | |
| 700 | 1 | |a Rodríguez-Pintó, Ignasi |e investigator |4 oth | |
| 700 | 1 | |a Lories, Rik |e investigator |4 oth | |
| 700 | 1 | |a De Langhe, Ellen |e investigator |4 oth | |
| 700 | 1 | |a Witte, Torsten |e investigator |4 oth | |
| 700 | 1 | |a Collantes, Eduardo |e investigator |4 oth | |
| 700 | 1 | |a Ortega-Castro, Rafaela |e investigator |4 oth | |
| 700 | 1 | |a Jiménez Gómez, Yolanda |e investigator |4 oth | |
| 700 | 1 | |a Chizzolini, Carlo |e investigator |4 oth | |
| 700 | 1 | |a Kovács, Laszló |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Arthritis & rheumatology (Hoboken, N.J.) |d 2014 |g 76(2024), 5 vom: 01. Apr., Seite 751-762 |w (DE-627)NLM234543671 |x 2326-5205 |7 nnns |
| 773 | 1 | 8 | |g volume:76 |g year:2024 |g number:5 |g day:01 |g month:04 |g pages:751-762 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/art.42789 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 76 |j 2024 |e 5 |b 01 |c 04 |h 751-762 | ||